Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Kidney function worsens soon after acute coronary syndrome

07 Dec 2019

Renal function appears to deteriorate immediately after the index acute coronary syndrome (ACS) event and stabilizes not during hospitalization but, on average, 2 weeks after, a recent study has shown. Serial measurement of cystatin C levels may help assess risks of mortality or ACS recurrence.

Using routine laboratory techniques, researchers measured the changes in creatinine and cystatin C levels in 844 ACS patients (median age, 62.5 years; 77.9 percent male) over time. The primary outcome was the effect of the marker trajectories on cardiovascular death or hospitalization for recurrent, nonfatal ACS. A subsample of 185 patients were selected for the analysis of washout patterns of the biomarkers.

A total of 687 samples were retrieved from the washout patients. Analysis of biomarker evolution found that cystatin C levels peaked on the third day after the index ACS episode, while creatinine reached its highest concentration on the sixth day. Estimated glomerular filtration rate (eGFR), on the other hand, reached its nadir on the fourth day.

The markers took different durations to stabilize. For instance, cystatin C concentrations stabilized after 11 days, such that its plateau was reached 13 days after the index event. Creatinine and eGFR each required 10 and 8 days to stabilize. In all three cases, stability was temporary.

Elevated cystatin C levels were significantly predictive of the primary endpoint (adjusted hazard ratio [HR], per standard deviation increase in 2log concentration, 1.63, 95 percent confidence interval [CI], 1.01–2.66; p=0.043). The same was true for its serial measurement >7 days after index ACS (adjusted HR, 1.63, 95 percent CI, 1.01–2.57; p=0.045).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.